5-Fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate

Introduction

Modern drug discovery increasingly depends on the precise design of complex heterocyclic molecules. In cardiovascular drug development, fluorinated heterocycles have become especially important because fluorine atoms can improve metabolic stability, optimize molecular interactions, and enhance pharmacokinetic performance.

One representative example is Vericiguat, an oral soluble guanylate cyclase (sGC) stimulator used in the treatment of certain forms of heart failure. The synthesis of Vericiguat involves a sequence of carefully controlled transformations, relying on high-quality intermediates that help establish its characteristic pyrazolopyridine framework.

Among these intermediates, Ethyl 5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate (CAS No. 1361232-72-5) serves as an important fluorinated building block in reported synthetic routes. Understanding why this intermediate is valuable helps explain broader trends in modern pharmaceutical chemistry.

Why Fluorinated Heterocycles Matter in Drug Design

Fluorine is one of the most frequently incorporated elements in contemporary small-molecule pharmaceuticals. Although replacing a hydrogen atom with fluorine causes only a modest structural change, it can significantly influence a molecule’s behavior.

Benefits commonly associated with fluorinated intermediates include:

• · Improved metabolic stability
• · Enhanced lipophilicity
• · Greater receptor-binding selectivity
• · Better oral bioavailability
• · Increased chemical stability during synthesis

These properties make fluorinated heterocycles attractive starting materials for medicinal chemists working on cardiovascular, oncology, antiviral, and central nervous system therapies.

Understanding the Intermediate

Product Name

Ethyl 5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate

CAS Number

1361232-72-5

Molecular Characteristics

This fluorinated pyrazolopyridine derivative combines several important structural features:

• · Pyrazolopyridine fused heterocycle
• · Fluorinated aromatic substituent
• · Ester functional group suitable for downstream conversion
• · Excellent synthetic versatility

The combination of these functional groups enables subsequent reactions such as hydrolysis, amidation, substitution, and cyclization during pharmaceutical manufacturing.

From Early Building Blocks to Advanced Vericiguat Intermediates

The construction of Vericiguat does not occur in a single reaction. Instead, chemists assemble the target molecule through multiple carefully designed intermediates.

One important upstream compound is:

Ethyl 5-amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate

Through a series of controlled synthetic transformations—including ring construction, selective fluorination, and functional group modification—this precursor can be converted into more advanced fluorinated pyrazolopyridine intermediates, including:

Ethyl 5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate

These intermediates contribute to the development of molecular frameworks reported in Vericiguat synthesis. Because every transformation depends on the quality of the preceding intermediate, maintaining high purity throughout the process is essential for successful scale-up.

Why Intermediate Quality Determines Manufacturing Success

When pharmaceutical companies evaluate intermediate suppliers, the focus extends beyond chemical purity alone.

Several manufacturing factors directly influence downstream process performance:

Consistent Batch Reproducibility

Reliable synthetic processes reduce variability and improve manufacturing efficiency.

Controlled Impurity Profiles

Minimizing process-related impurities simplifies purification and supports regulatory expectations.

Process Scalability

An intermediate that performs well in laboratory synthesis should maintain consistent quality during kilogram-scale and commercial production.

Supply Chain Reliability

Long-term pharmaceutical manufacturing requires dependable production capacity and uninterrupted global supply.

For these reasons, experienced manufacturers of fluorinated heterocyclic intermediates play an increasingly important role in pharmaceutical development.

Market Drivers Behind Vericiguat-Related Intermediates

Several industry trends continue to strengthen demand for advanced cardiovascular pharmaceutical intermediates.

Increasing Global Burden of Heart Failure

Heart failure remains one of the leading causes of hospitalization worldwide, supporting continued investment in innovative treatment options.

Continued Innovation in Small-Molecule Therapeutics

Despite advances in biologics, orally administered small-molecule drugs remain highly attractive because of patient convenience and manufacturing efficiency.

Growing Demand for Fluorinated Pharmaceutical Chemistry

Fluorinated intermediates continue expanding across numerous therapeutic areas, encouraging pharmaceutical companies to establish long-term sourcing partnerships.

SHLZ Pharma: Supporting Complex Pharmaceutical Synthesis

SHLZ Pharma specializes in the research, development, and manufacture of pharmaceutical intermediates for global customers.

Our manufacturing capabilities include:

Advanced Fluorination Chemistry

Extensive experience with fluorinated aromatic compounds and heterocyclic intermediates.

Optimized Synthetic Routes

Continuous process improvement enhances production efficiency while maintaining consistent product quality.

Flexible Manufacturing Scale

Support from laboratory development through pilot production and commercial manufacturing.

Comprehensive Quality Assurance

Strict analytical testing ensures product consistency, traceability, and customer confidence.

International Supply Experience

Serving pharmaceutical companies, CROs, CDMOs, and research institutions across multiple international markets.

Key Considerations When Selecting a Pharmaceutical Intermediate Supplier

Before choosing a manufacturing partner, pharmaceutical companies typically evaluate several factors:

• · Can the supplier consistently deliver high-purity products?
• · Is commercial-scale manufacturing available?
• · Does the supplier have expertise in fluorinated chemistry?
• · Are customized synthesis services available?
• · Can documentation and technical support meet project requirements?

Selecting an experienced supplier reduces development risks while improving supply chain stability throughout the product lifecycle.

Conclusion

The development of innovative cardiovascular therapies increasingly depends on sophisticated fluorinated intermediates. Ethyl 5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate (CAS No. 1361232-72-5) represents an important building block in reported synthetic pathways related to Vericiguat, while upstream compounds such as Ethyl 5-amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate illustrate the complexity of modern pharmaceutical synthesis.

By combining expertise in fluorinated chemistry, robust manufacturing capabilities, and a commitment to quality, SHLZ Pharma supports pharmaceutical innovators with reliable intermediate solutions for research, development, and commercial production.